Insulin-like growth factor mecasermin

Insulin-like growth factor (mecasermin) [SED-15, 1792 SEDA-32, 676]... 

A small number of children with growth failure have severe IGF-1 deficiency that is not responsive to exogenous GH. Causes include mutations in the GH receptor and development of neutralizing antibodies to GH. In 2005, the FDA approved mecasermin for treatment of severe IGF-1 deficiency that is not responsive to GH. Mecasermin is a complex of recombinant human IGF-1 (rhIGF-1) and recombinant human insulin-like growth factor-binding protein-3 (rhIGFBP-3). 

Insulin-like growth factor 1/insulin 36.4 growth factor-binding protein 3 complex IGF-1/IGFBP-3 mecasermin rinfabate (IPLEX)... 

Injectable recombinant human insulin-like growth factor (rhIGF-I rINN mecasermin) has been available for nearly 20 years for treatment of the rare instances of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies. It has also been used as an insulin-sensitizing agent in severe insulin-resistant conditions. Adverse reactions to mecasermin have been reviewed [24 ]. The most common adverse reaction is hypoglycemia, which is readily controlled by administration with meals. 

Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009 26(1) 40-54. 

---